Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance
US10544213B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 12, 2015 |
| Grant date | Jan 28, 2020 |
| Priority date | — |
| Expiry date | Jun 24, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced β-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.